![Yuan Xu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yuan Xu
Directeur/Membre du Conseil chez
FATE THERAPEUTICS, INC.
Fortune : 23 406 $ au 30/06/2026
Profil
Yuan J.
Xu is currently an Independent Director at Fate Therapeutics, Inc. since 2021 and an Independent Director at Xilio Therapeutics, Inc. since 2022.
Former roles include Chief Executive Officer & Director at Legend Biotech Corp.
from 2018 to 2020, Independent Director at Akero Therapeutics, Inc. from 2021 to 2025, Vice President-Biologics at Gilead Sciences, Inc. from 2014 to 2015, Senior Vice President at Merck & Co., Inc. from 2015 to 2017, and Vice President at Novartis AG from 2008 to 2014.
Education includes a doctorate from the University of Maryland and an undergraduate degree from Nanjing University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/06/2026 | 8 669 ( 0,01% ) | 23 406 $ | 30/06/2026 | |
LEGEND BIOTECH CORP. -.--% | 08/06/2020 | 0 ( -.--% ) | - $ | 30/06/2026 |
| 11/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Postes actifs de Yuan Xu
| Sociétés | Poste | Début |
|---|---|---|
| FATE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 03/08/2021 |
| XILIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 04/01/2022 |
Anciens postes connus de Yuan Xu
| Sociétés | Poste | Fin |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 09/12/2025 |
| LEGEND BIOTECH CORPORATION | Directeur Général | 01/08/2020 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/08/2017 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/08/2015 |
| NOVARTIS AG | Corporate Officer/Principal | 01/01/2014 |
Formation de Yuan Xu
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
65
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
University of Maryland
 University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nanjing University
 Nanjing University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fate Therapeutics, Inc.
 Fate Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Legend Biotech Corp.
 Legend Biotech Corp. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which engages in the discovery and development of novel cell therapies for oncology | Health Technology |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Akero Therapeutics, Inc.
 Akero Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for patients with metabolic diseases | Health Technology |
Choisissez Zonebourse 
